Amicus' Phase III study of AT-GAA in Pompe disease failed to meet its primary endpoint, raising questions about the combination's approval prospects. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
